2196 — Shanghai Fosun Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapNeutral

Market Cap
HK$52.90bn
Enterprise Value
HK$93.26bn
Revenue
CNY41.66bn

Annual income statement for Shanghai Fosun Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	39,005	43,952	41,400	41,067	41,662
Cost of Revenue
Gross Profit	18,712	20,696	19,683	19,641	20,784
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	32,710	39,309	38,097	36,844	36,443
Operating Profit	6,295	4,642	3,302	4,223	5,219
Other Net Non Operating Costs
Net Income Before Taxes	6,054	4,574	3,265	4,169	5,112
Provision for Income Taxes
Net Income After Taxes	4,987	3,947	2,895	3,512	4,248
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,735	3,731	2,386	2,770	3,371
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,735	3,731	2,386	2,770	3,371
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.24	1.34	0.69	0.765	0.964
Dividends per Share